-
Ahead Of Merck's Keytruda PDUFA Date, Analyst Says Expect Approval
Wednesday, May 3, 2017 - 2:41pm | 407Read More...Merck & Co., Inc. (NYSE: MRK) traders that haven't already done so should mark May 10 on their calendars. The company announced in early January the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab)....
-
Merck's Q2 Good, But Not Good Enough, Says BMO
Monday, August 1, 2016 - 2:12pm | 471Read More...Despite topping the Street view, BMO said the second-quarter results of Merck & Co., Inc. (NYSE: MRK) is not "good enough" to change its Market Perform rating on the stock. Merck's quarterly revenue was about 1 percent above consensus and 1.5 percent above BMO's forecast, while EPS of $0.93 was...
-
BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
Monday, July 18, 2016 - 12:02pm | 586Read More...BMO has downgraded Merck & Co., Inc. (NYSE: MRK) shares to Market Perform from Outperform on valuation. "The so called 'TINA' (there is no alternative) effect is not enough for us to remain bullish at these levels; the fundamentals have not improved to justify higher valuations. In fact, we are...
-
Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds
Saturday, December 12, 2015 - 3:05pm | 705Read More...The global pharmaceutical industry has experienced a plethora of successful new products within the sector, more than offsetting global pricing pressures and supporting an outlook change to positive from stable for the entire industry. JPMorgan projects several important product launches and...
-
Bank Of America On Merck: 'MAGNIF-TECOS!'
Tuesday, April 28, 2015 - 9:30am | 327Read More...In a report published Tuesday, Bank of America analyst Colin Bristow commented on Merck & Co., Inc. (NYSE: MRK)'s announcement of top-line results for the TECOS trial, noting that the study met its primary endpoint of non-inferiority versus placebo for the composite CV endpoint. The...
-
SunTrust's Latest Comments On Merck
Wednesday, April 15, 2015 - 3:32pm | 285Read More...In a report published Tuesday, SunTrust Robinson Humphrey analyst John Boris discussed the FDA AdCom's vote to add safety warnings to AstraZeneca plc (NYSE: AZN)'s Onglyza and Takeda's Nesina, which is a positive for Merck & Co., Inc. (NYSE: MRK)'s Januvia franchise. The FDA AdCom voted that...
